Lyra Therapeutics (LYRA) Other financing activities (2019 - 2024)
Lyra Therapeutics (LYRA) recorded quarterly Other financing activities of $3000.0 in Q1 2024, up 50.0% on a QoQ basis from $2000.0 in Q3 2023, and down 25.0% YoY from $4000.0 in Q2 2023.
Lyra Therapeutics (LYRA) Other financing activities (2019 - 2024) Analysis & Trends
Lyra Therapeutics (LYRA) has reported Other financing activities for 6 consecutive years, with $3000.0 the latest figure, recorded in Q1 2024.
- Other financing activities for Q1 2024 came in at $3000.0, down 25.0% year-over-year; the trailing twelve-month figure through Dec 2024 was $3000.0 (down 97.09% YoY), and the FY2024 annual result was $3000.0, down 97.09% from the prior year.
- Other financing activities for Q1 2024 stood at $3000.0, up from $2000.0 in the prior quarter.
- The five-year high for Other financing activities was $59.9 million in Q4 2020, with the low at -$59.9 million in Q3 2020.
- A 5-year average of $71800.0 and a median of $9500.0 in 2021 frame the typical range for Other financing activities.
- The widest YoY moves for Other financing activities: up 2994450.0% in 2020, down 272331.82% in 2020.
- Lyra Therapeutics' Other financing activities stood at $59.9 million in 2020, then plunged by 99.98% to $11000.0 in 2021, then retreated by 27.27% to $8000.0 in 2022, then sank by 75.0% to $2000.0 in 2023, then soared by 50.0% to $3000.0 in 2024.
- The last three Other financing activities figures came in at $3000.0 (Q1 2024), $2000.0 (Q3 2023), and $97000.0 (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 3,000.00 |
| Mar 31, 2024 | 3,000.00 |
| Sep 30, 2023 | 2,000.00 |
| Sep 30, 2023 | 2,000.00 |
| Jun 30, 2023 | 97,000.00 |
| Jun 30, 2023 | 97,000.00 |
| Mar 31, 2023 | 4,000.00 |
| Mar 31, 2023 | 4,000.00 |
| Mar 31, 2022 | 8,000.00 |
| Mar 31, 2022 | 8,000.00 |
| Sep 30, 2021 | 11,000.00 |
| Sep 30, 2021 | 11,000.00 |
| Jun 30, 2021 | 331,000.00 |
| Jun 30, 2021 | 331,000.00 |
| Mar 31, 2021 | 262,000.00 |
| Mar 31, 2021 | 262,000.00 |
| Dec 31, 2020 | 59.89 Mn |
| Dec 31, 2020 | 59.89 Mn |
| Sep 30, 2020 | -59.89 Mn |
| Sep 30, 2020 | -59.89 Mn |